Merck Sharp and Dohme to present new Zepatier data at Liver Meeting

Merck Sharp and Dohme has announced plans to present clinical data on a number of hepatitis C therapies at this year's Liver Meeting.

Taking place in Boston from November 11th to 15th, the annual American Association for the Study of Liver Diseases (AASLD) conference will see Merck present 15 scientific abstracts, including seven oral and eight poster presentations.

These will highlight findings from the company's hepatitis C virus clinical development programmes, including evaluations of Zepatier and the company's investigational therapy MK-3682B in a broad range of patients with chronic hepatitis C infections.

Zepatier will be a particular focus of the presentations, with the elbasvir and grazoprevir combination therapy having been approved in the US and Europe earlier this year.

Dr Eliav Barr, senior vice-president for global clinical development, infectious diseases and vaccines at Merck Research Laboratories, said: "At AASLD this year, researchers will share data from numerous studies that are underway to better understand the potential of Zepatier and our investigational medicines in diverse patient populations."

The company has been developing treatments for chronic hepatitis C infections for more than 30 years.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.